Clinical trials: Atypical Hyperplasia
Endometrial Cancer, Endometrial Cancer Precursors
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
BACKGROUND: Endometrial cancer is a common and deadly cancer for women. It is getting more common and deadly because risk factors like age and obesity are increasing.
- Conditions
- Endometrial Cancer, Endometrial Cancer Precursors, Ovarian Cancer, Complex Atypical Endometrial Hyperplasia
- Trial name
- DETECT (NCT03538665)
- Where
- United States
- Volunteers
- 1,700 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Abnormal Uterine Bleeding (AUB), Endometrial Cancer
Endometrial Cancer Vaginal Fluid Specimen Collection Study
This is a multicenter, prospective, specimen collection study for development and evaluation of tests used to detect endometrial cancer, other cancers, or their causes.
- Conditions
- Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
- Trial name
- ENVISION (NCT07544680)
- Where
- 5 sites in United States
- Volunteers
- 4,200 people
- Sponsor
- Exact Sciences Corporation
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer.
- Trial name
- NCT04576104
- Testing
- Biopsy Procedure, Extended Release Metformin Hydrochloride, Megestrol Acetate
- Where
- 8 sites in United States
- Volunteers
- 51 people
- Sponsor
- Northwestern University
Breast Cancer
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
The overall goal of this project is to develop an integrative system of breast cancer risk assessment based on epidemiologic and biologic risk variables, as well as to develop or refine risk biomarkers which may be useful in…
- Trial name
- NCT00291096
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
This randomized phase II trial studies how well levonorgestrel-releasing intrauterine system works when given alone or with everolimus in treating patients with atypical hyperplasia (a pre-cancerous growth of the lining of the…
- Conditions
- Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
- Trial name
- LEVER (NCT02397083)
- Testing
- Everolimus, Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System
- Where
- 18 sites in United States
- Volunteers
- 102 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms
Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy
The goal of this study is to determine how often patients who have atypical lobular hyperplasia (ALH) or lobular carcinoma in situ (LCIS) on core needle biopsy of an imaging (found by mammogram or breast ultrasound) abnormality…
- Trial name
- NCT00146536
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
An Examination of Predictors of Indicators of Response to Celecoxib in Women Who Have a Diagnosis of Early Breast Cancer
To assess the quantitative real time PCR results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.
- Trial name
- NCT00291122
- Testing
- celecoxib 400 mg BID
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Kansas
Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia
Ruxolitinib for Premalignant Breast Disease
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for…
- Conditions
- Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
- Trial name
- TBCRC042 (NCT02928978)
- Testing
- Ruxolitinib
- Where
- 8 sites in United States
- Volunteers
- 84 people
- Sponsor
- Julie Nangia
Endometrial Hyperplasia
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia
The purpose of this research study is to compare the uterus tissue of women who receive an intrauterine system to treat their endometrial hyperplasia with the uterine tissue of women who receive megestrol acetate to treat their…
- Trial name
- NCT04897217
- Testing
- Megestrol Acetate, Levonorgestrel Drug Implant
- Sponsor
- Wake Forest University Health Sciences
Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia
Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer
This randomized clinical trial studies a group-based lifestyle intervention or usual care in measuring biomarker levels in participants at high risk for breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Atypical Lobular Breast Hyperplasia, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier
- Trial name
- DEEM (NCT01874184)
- Testing
- counseling intervention, behavioral dietary intervention, exercise intervention
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Endometrial Neoplasms, Endometrial Cancer
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
This is a single-center, randomized, open-label, controlled clinical trial evaluating whether adding orlistat to standard progestin therapy can improve treatment response in patients receiving fertility-sparing treatment for…
- Conditions
- Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance
- Trial name
- PKUPH-ORLPP-EC (NCT07714070)
- Testing
- Orlistat, Progestin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University People's Hospital
Breast Fibroadenoma, Atypical Ductal Hyperplasia
Comparing Vacuum-Assisted Percutaneous Excision to Open Surgical Excision for Borderline or High-Risk Breast Lesions
This randomized controlled trial compares vacuum-assisted percutaneous excision to open standard surgical excision in women who have high-risk or borderline, non-malignant breast lesions with respect to efficacy, safety, cosmesis…
- Conditions
- Breast Fibroadenoma, Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, Lobular Carcinoma in Situ
- Trial name
- VAPEX (NCT03868475)
- Testing
- Vacuum-assisted percutaneous excision, Open surgical excision
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Complex Atypical Hyperplasia, Endometrial Cancer
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
Purpose: The purpose of this study is to evaluate FFNP PET/MRI's utility for predicting response to Levonorgestrel-releasing Intrauterine Device (LR-IUD) hormonal therapy for Complex Atypical hyperplasia (CAH) and Endometrial…
- Trial name
- NCT05483023
- Testing
- 18F-fluorofuranylnorprogesterone PET / MRI
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Atypical Endometrial Hyperplasia
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
To see if megestrol acetate plus rosuvastatin will be superior to reversing the endometrial lesion to a normal endometrium than megestrol acetate alone in patients with atypical endometrial hyperplasia (AEH).
- Trial name
- NCT04491682
- Testing
- Megestrol Acetate, Rosuvastatin
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Fudan University
Complex Endometrial Hyperplasia With Atypia, Grade 1 Endometrial Endometrioid Adenocarcinoma
Improving the Treatment for Women With Early Stage Cancer of the Uterus
Currently the standard treatment for early stage endometrial cancer or endometrial hyperplasia with atypia is a total hysterectomy (an operation to remove the uterus) and removal of both ovaries.
- Trial name
- feMMe (NCT01686126)
- Testing
- Levonorgestrel, Metformin
- Where
- 17 sites in Australia, New Zealand
- Volunteers
- 165 people
- Sponsor
- Queensland Centre for Gynaecological Cancer
Fertility-Sparing Treatment (FST), Atypical Endometrial Hyperplasia
Ultrasound and Histology in AEH and Early EEC Treated Conservatively
Ultra-S.A.F.E. is a multicenter, ambispective observational study investigating the ultrasound and histological characteristics of patients with atypical endometrial hyperplasia (AEH) or endometrioid endometrial carcinoma (EEC)…
- Conditions
- Fertility-Sparing Treatment (FST), Atypical Endometrial Hyperplasia, Early Endometrial Cancer (EEC)
- Trial name
- ULTRA-SAFE (NCT07028242)
- Testing
- Hysteroscopic fertility-sparing surgery and hormonal treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Endometrial Atypical Hyperplasia, Endometrial Adenocarcinoma
Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
The purpose of this study is to see if megestrol acetate plus metformin will be more effective in returning the endometrial tissue to a normal state than megestrol acetate alone in patients with endometrial atypical hyperplasia…
- Trial name
- NCT01968317
- Testing
- Megestrol acetate and metformin, Megestrol acetate
- Where
- 5 sites in China
- Volunteers
- 150 people
- Sponsor
- Xiaojun Chen
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
This study evaluates whether adding a polygenic risk score evaluation to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about accepting additional breast cancer…
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05755269
- Testing
- Biospecimen Collection, Genotyping, Survey Administration
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Atypical Endometrial Hyperplasia, Human Papillomavirus Infection
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
This research trial studies carbonic anhydrase 9 (CA-IX), p16, proliferative markers, and human papilloma virus (HPV) in diagnosing cervical lesions in patients with abnormal cervical cells.
- Conditions
- Atypical Endometrial Hyperplasia, Human Papillomavirus Infection, Stage 0 Cervical Cancer AJCC v7
- Trial name
- NCT00892866
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- 163 sites in United States, Japan and 1 more
- Volunteers
- 877 people
- Sponsor
- GOG Foundation
Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
This pilot phase IIa trial studies how well exemestane works in treating patients with complex atypical hyperplasia of the endometrium/endometrial intraepithelial neoplasia or low grade endometrial cancer.
- Conditions
- Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT03300557
- Testing
- Exemestane, Laboratory Biomarker Analysis, Pharmacokinetic Study
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)